This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lass-Flörl, C.
Right arrow Articles by Rodriguez-Tudela, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lass-Flörl, C.
Right arrow Articles by Rodriguez-Tudela, J. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2009, p. 794-795, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.00335-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus: Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing{triangledown}

Cornelia Lass-Flörl,1* Ana Alastruey-Izquierdo,2 Manuel Cuenca-Estrella,2 Susanne Perkhofer,1 and Juan Luis Rodriguez-Tudela2

Department of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University, Innsbruck, Austria,1 Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Spain2

Received 11 March 2008/ Returned for modification 30 June 2008/ Accepted 30 November 2008

This study presents in vitro susceptibility data for clinical (n = 48) and environmental (n = 31) isolates of Aspergillus terreus against nine antifungal agents. The methodology of the European Committee on Antimicrobial Susceptibility Testing was applied. Posaconazole and anidulafungin had the lowest and amphotericin B the highest MICs. No differences in susceptibility patterns were observed between environmental and clinical isolates.

* Corresponding author. Mailing address: Innsbruck Medical University, Department of Hygiene, Microbiology and Social Medicine, Fritz Pregl Str. 3/III, Innsbruck 6020, Austria. Phone: 43 0512 9003 70725. Fax: 43 0512 9003 73700. E-mail: cornelia.lass-floerl{at}i-med.ac.at

{triangledown} Published ahead of print on 8 December 2008.

Antimicrobial Agents and Chemotherapy, February 2009, p. 794-795, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.00335-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»